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ABSTRACT 
 
This protect aims to evaluate alternative strategies to screen for cervical cancer 
including liquid-based cytology (LBC) with supplementary reflex testing for human 
papillomavirus (HPV), p16INK4a, HPV-L1 capsid protein, and miR-205 for use as 
possible diagnostic and prognostic markers in women with abnormal findings detected 
through the organized cervical cancer screening program.  
 
This split-sample study enrolled 137 women with atypical Pap smear findings to 
compare the effectiveness of conventional cytology (CC) with LBC cytology for 
cervical cancer screening. Sensitivity to detect cervical intraepithelial neoplasia (CIN 
2+) was 47% for CC compared with 66% for LBC. These results from these two 
sampling techniques agreed with histological findings in 37% and 53% of cases, 
respectively, a statistically significant difference. The significant advantage of 
improved sensitivity combined with the ability to carry out reflex testing for diagnostic 
and prognostic markers such as HPV DNA or p16 INK4a without repeated sampling 
favors LBC for a possible future role as a screening technique.  
 
In cases of low-grade cytological abnormalities combining LBC with HPV triage 
(LBC+HPV triage) may improve detection of CIN compared with CC. Our study found 
that CC and LBC+HPV triage produced similar detection rates of CIN2+. When 
comparing CIN detection rates the adjusted OR for CIN2+ was 0.87 (95% CI: 0.60-
1.26) and for CIN3+ 1.00 (95% CI: 0.64-1.58). Consequently, the use of LBC+HPV 
triage offered no advantage over conventional cytology regarding sensitivity and 
specificity or positive and negative predictive value for detection of histologically 
confirmed CIN2+. Nevertheless, LBC+HPV triage may potentially reduce unnecessary 
medical procedures and testing among HR-HPV-negative women with findings of 
abnormal cytology.  
 
 
 
We analyzed 118 patient samples of dysplastic cells using immunocytochemical 
staining to assess the expression of p16INK4a. Expression levels of p16INK4a, correlated 
with CIN grade, showing stronger reactivity in higher grade lesions. We found a 
stronger correlation between severity of cytological abnormality and p16INK4a, 
immunoreactivity when the diagnosis was simultaneously confirmed by routine 
cytology (p<0.001, χ2 exact test for trend). This staining technique may be able to serve 
as a complementary prognostic marker when used as a reflex test to identify women at 
risk of cervical cancer. 
 
We also used immunocytochemistry to detect L1 capsid protein in HR-HPV-positive 
women who displayed minor cytological abnormalities. Progression to CIN2+ occurred 
in 2 of 13 L1-positive women (15.0%) infected with HPV16, compared with 4 L1-
positive women infected with other HR-HPV types. Among all L1-positive women 
with CIN2+, 35.7% were infected with both HR and low-risk (LR) HPV types, 25.0% 
with HR-HPV types only and 13.3% with HPV16. Loss of previously positive L1 
expression may serve as a prognostic marker for preinvasive cervical lesions. 
 
We carried out reverse transcription quantitative PCR (RT-qPCR) on our LBC samples 
to assess miR-205 expression and correlate these results with histology. Regardless of 
whether findings were based on histology or cytology, our results showed no significant 
changes in miR-205 expression relating to different stages of disease progression. It 
may be that the increased expression of miR-205 is not stage-specific, but could 
represent a continuous process throughout disease progression, although we cannot 
conclude this with certainty.Cervical cancer could become one of our most preventable 
cancers by effectively combining vaccination programs against HR-HPV with 
improved detection of precursors by integrating molecular markers into screening 
programs.  
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1. POPULÄRVETENSKAPLIG SAMMANFATTNING 
Cervixcancer (cxca) (livmoderhalscancer) är i världen en av de vanligaste 
cancerformerna hos kvinnan och kan med dagens teknologi förebyggas. Detta har i 
Sverige varit målsättning att med hjälp av den organiserade cellprovskontrollen kunna 
sänka mortaliteten. Det förefaller som vi med stor framgång sedan 1960-talets mitt har 
lyckats sänka cancer frekvensen med mer än hälften trots det enstaka provets 
begränsade sensitivitet på 50-70 %. Begränsade faktorer för programmets effektivitet 
är framför allt graden av hörsamhet och det cytologiska provets känslighet. Detta 
kompenseras genom tämligen korta intervall för provtagning. Med ett sådant intervall 
på 3 år testas kvinnan i genomsnitt med ca 12 prover under sin livstid, förutsatt att 
kvinnan hörsammat alla kallelser. Denna provtagnings frekvens ger en mycket hög 
känslighet för att i något av dessa prover kunna diagnostisera en förändring som 
behandlingsbar. En av förutsättningarna för den framgångsrika cellprovskontrollen har 
varit att den cytologiska diagnostiken utförts med tillräcklig noggrannhet samtidigt som 
man gör ansträngningar för att undvika överdiagnostik.  
 
De svåraste cytologiska bedömningarna är gränsvärden mellan tidiga cellförändringar 
och reaktiva förändringar. Det rekommenderas i Sverige att diagnostiken ska drivas så 
att ca 5 % av cellproverna rapporteras som avvikande. Denna siffra skall ses mot 
bakgrund av den totala livstidsrisken att utveckla cervixcancer, som är under 1 %. Låg 
specificitet för dessa svårbedömda förändringar som inte har med cancerutvecklingen 
att göra. Dessa uppföljande undersökningar skapar dels onödig oro hos en stor grupp 
friska kvinnor och bidrar dessutom till betydande kostnader för samhället. 
Konventionell gynekologisk provtagningsteknik med cellutstryk på objektglas har, trots 
framgångsrik tillämpning, en begränsad möjlighet till kompletterade analyser. Kvinnan 
måste kallas tillbaka för ytterligare en provtagning vilket skapar onödig oro och 
begränsar samtidigt provets reproducerbarhet och sensitivitet. Det konventionella 
provet har på grund av sin hantering en stor risk för artefakter med lufttorkade celler, 
som försvårar diagnostiken och därmed minskar provets specificitet.  
 
Alternativa provtagningstekniker för cellprover har utarbetats, och dessa förbättrar 
betydligt provets kvalitet. Den vätskebaserade tekniken innebär att provtagaren direkt 
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slammar upp provet i en buffrad fixeringslösning, (vätskebaserad cytologi, liquid-based 
cytology, LBC), i stället för att cellerna stryks ut på ett objektglas. LBC-provet behålls 
sedan i detta fixativ tills man på laboratoriet överför cellerna till objektglas. Tekniken 
ger morfologiskt bättre bevarade celler och när denna teknik testas på olika laboratorier 
har detta ibland, men inte alltid, höjt provets sensitivitet. Vid den cytologiska 
bedömningen av dessa preparat används bara en mindre del av provet till 
rutindiagnostik, dvs. en betydande del av provet finns kvar för kompletterande analyser 
som gör det möjligt att öka provets specificitet. En sådan hjälpanalys kan vara påvisande 
av högrisktyper av humant papillomavirus (HR-HPV). Med LBC kan detta utföras utan 
att kvinnan behöver kallas till kompletterade undersökningar (s.k.”reflex-screening”), 
och om de förändrade cellerna inte innehåller HR-HPV kan onödig uppföljning och oro 
undvikas. 
 
I dag vet vi att i princip all cxca orsakas av en persisterande infektion med HR-HPV. 
HR-HPV är en nödvändig men inte en tillräcklig förutsättning för en cancerutveckling 
i cervix. Viruset skadar cellens genetiska stabilitet och är närvarade under hela 
carcinogenesen. E6 och E7 generna i HR-HPV vironen driver utvecklingen av 
precancerösa cellförändringar genom att blockera tumörsupressor proteinerna p53 och 
pRb, vilket avsevärt ökar risken för genetiska skador och klonal utmognad. I avancerade 
förändringar integreras HPV genomet med värdcellens kromosomer vilket ökar 
förmågan hos E6 och E7 att initiera en neoplastisk transformation. 
Flertalet infektioner med HR-HPV läker spontant, och infektionen är inte den enda 
faktorn som leder till utveckling av cancer. Om sådana riskfaktorer kan identifieras 
skulle det öka förståelsen för den HPV-relaterade cancerutvecklingen. Eventuellt skulle 
detta också ge möjlighet att med specifikt identifiera de kvinnor som löper risk att 
utveckla cancer. De senaste årens framsteg inom molekylärbiologi och genteknologi 
öppnar helt nya möjligheter till en ytterligare optimerad diagnostik för att kunna öka 
det diagnostiska utbytet av materialet. Dessa tekniker kan användas vid undersökningar 
av det vätskebaserade provet.  
 
Denna studie syftar till att studera hur man med denna provtagningsmetodik kan 
kombinera informationen från cytologiska, virologiska och molekylärbiologiska 
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analyser från ett och samma prov, för att mer specifikt hitta de kvinnor som löper riska 
att utveckla cervixcancer. 
 
Det första arbete ville kartlägga i vad mån LBC kan ge högre känslighet att hitta en 
höggradig cellförändring i jämfört med konventionellt tagna prover på ett laboratorium 
med lång cytologisk erfarenhet. Resultatet visade att en ökad känslighet för LBC i 
kombination med möjligheten till reflex-analys såsom, HPV DNA eller p16INK4a 
immuncytokemi utan förnyad provtagning, gör LBC teknologin till en viktig 
provtagningsmetod med betydande fördelar. 
 
Med den andra studien ville vi i större skala utvärdera de båda teknikerna för 
provtagning. Känsligheten för LBC teknologins utförande minskade när tekniken 
implementerades inom det populationsbaserade screeningsprogrammet. Studien 
reflekterade även upplärningsprocessen som förbättrades med tiden efter att tekniken 
blev implementerad.  
 
I det tredje delarbetet studerade vi om upplagring av p16INK4a protein (”cancermarkör”), 
i immuncytokemisk metod, kan närvara vid en HPV-orsakad cellförändring. Studien 
visade goda resultat där p16INK4a upplagring i cellkärnan ej påvisades i några normala 
celler utan enbart i avancerade cellförändringar, histologiskt verifierade. Detta gör att 
denna ”biomarkör” kan användas för att öka känsligheten att hitta höggradiga 
cellförändringar i ett cellprov som vidare behöver följas upp. 
 
Syftet med den fjärde studien var att studera HPV L1 capsid protein som kan ha en 
självläkande effekt hos kvinnor med en HPV infektion. Studien visade att utryck av L1 
proteinet i cellkärnan var mer associerad till lättare cellförändringar än till höggradiga 
cellförändringar och att ett L1 uttryck kan initiera en spontanläkning. Tillsammans med 
p16INK4a kan HPV L1 förbättra diagnostiken för att mer specifikt hitta de kvinnor som 
löper risk att utveckla livmoderhalscancer.  
 
I den femte studien testade vi hypotesen att nivåer av ett specifict microRNA uttryck 
förändras i takt med cancerutvecklingen. Resultatet visade att få tumörceller i 
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förhållande till normala celler och närvaro av tumörnekros, gör LBC mindre lämplig 
som metod för denna analys. 
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2. INTRODUCTION 
Cervical cancer (cxca) is one of the most common cancers among women worldwide. 
The goal in Sweden has been to reduce mortality through a population-based screening 
program, which since 1965 has cut mortality from cxca by more than half despite 
limited sensitivity of about 70% for a single Pap smear. This limited sensitivity is 
partially compensated by relatively short sampling intervals. A successful screening 
program requires sufficient predictive value (PV) for the diagnosis. Low predictive 
power (LPP) for minor cytological abnormalities results in a large number of follow-up 
cases for which risk for developing cancer is low, thereby causing unnecessary concern 
for a large group of healthy women and resulting in substantial costs to society.  
 
Conventional gynecological sampling with the Papanicolaou (Pap) smear offers limited 
opportunity for supplementary analyses. Samples taken using liquid-based cytology 
(LBC) techniques preserve cellular morphology better, which has the advantage of 
increasing sensitivity and the material can also be used for reflex-testing to improve 
specificity. LBC technology with reflex-testing for high-risk Human papillomavirus 
(HR-HPV) DNA has now become an established method for improving test 
performance. 
 
Today we know that virtually all cxca is caused by persistent HR-HPV infection. High-
risk HPV infection is a necessary, albeit insufficient, risk factor on its own for causing 
cxca. The virus interferes with cellular genetic stability and is present throughout the 
entire process of carcinogenesis. The E6 and E7 HPV oncogenes inhibit the effect of 
tumor suppressor proteins, protein 53 (p53) and Retinoblastoma protein (pRb), thereby 
increasing the risk of mutations. Most HR-HPV infections are transient. Additional as 
yet unknown factors are necessary for development of cxca. Identification of such risk 
factors would improve understanding of HPV-related cancer development. 
 
The aim of this project was to evaluate what additional diagnostic protection LBC offers 
in cytology screening and to search for diagnostic and prognostic markers in LBC 
samples. The HPV L1 capsid protein, p16INK4a, and microRNA are two such 
interesting candidate markers that can be analyzed in LBC samples. Effective use of 
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complementary analyses such as these will help to more specifically identify women at 
risk for developing cxca. 
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3. BACKGROUND 
3.1. THE UTERINE CERVIX 
The uterine cervix is the distal end of the uterus that protrudes into the upper vagina. 
The cervix is about two-three cm long and about two cm in diameter (Figure 1). The 
vaginal part of the cervix, the ectocervix, is primarily covered with non-keratinized 
stratified squamous epithelium which potentially may become keratinized. Cell division 
is normally confined to the basal cells of the basement membrane. As the parabasal cells 
detach from this membrane they begin to differentiate, eventually forming the 
intermediate and superficial cell layers. This maturation process take 6-12 days in fertile 
women (Doorbar, 2013).The endocervical canal (endocervix) is lined with mucus-
secreting columnar cells. 
  
Figure 1. The female internal organs. The uterine cervix incircled. Colposcopy, cytology and 
histopathology pictures. With permission from : http://screening.iarc.fr 
 
    
Figure 2. The uterine cervix and transformation zone. Colposcopy, cytology and 
histopathology pictures. With permission from: http://screening.iarc.fr  
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The boundary between squamous and columnar epithelium is called the 
squamocolumnar junction (Figure 2). Before puberty and after menopause this junction 
is not found on the ectocervix. Instead, in post-menopausal women the epithelium 
becomes atrophic, causing the junction to migrate up into the cervical canal. In fertile 
women squamous metaplasia is common in this junction (Schiffman, Castle, Jeronimo, 
Rodriguez, & Wacholder, 2007), forming the transformation zone (TZ). The 
metaplastic epithelium of the TZ is thin  
(Figure 3), which makes the basal cells anchored to the basement membrane sensitive 
to infectious agents with a potential for malignant transformation (Doorbar et al., 2012; 
Sellors J.W., 2003). 
 
 
Figure 3. The cervical transformation zone. With permission from Mark Schiffman, 
Bethesda USA. 
 
 
3.2. CERVICAL CANCER 
Cervical cancer (cxca) is a current global health problem. This preventable disease 
accounts for almost 12% of all female cancers worldwide and is the fourth most 
common cause of cancer mortality among women. Worldwide there are almost 528,000 
new cases of this disease per year, resulting in more than 265,000 deaths annually 
(Ferlay et al., 2015). The incidence is considerably higher in developing countries, 
where more than 87% of cases can be found. Thus incidence varies geographically and 
in some regions this disease is the most common type of cancer (Figure 4). The rate of 
cxca is especially high, over 30 per 100,000, in East Africa (42.7) and Melanesia (33.3), 
as well as Southern (31.5) and Middle (30.6) Africa. The average global incidence is 
14/100,000 with a mortality rate of 6.8/100,000.  
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In Sweden, the corresponding figures are 7.4/100,000 and 1.9/100,000, respectively, 
while in countries such as Tanzania these figures are as high as 40.6/100,000 and 
32.5/100,000 annually (Ferlay, et al., 2015).The lowest incidence rates can be found in 
Western Asia (4.4/100,000) and Australia/New Zealand (5.5/100,000). European 
countries such as Switzerland, Malta, Cyprus and Finland have the lowest incidence 
with about 4/100,000 annually, while Romania, Lithuania and Bulgaria have much 
higher rates with over 24/100,000 women-years (Ferlay, et al., 2015). 
 
 
 
 
Figure 4. Incidence data per 10.000. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, 
Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012, Cancer Incidence 
Worldwide: IARC CancerBase No. 11  Available from: http://globocan.iarc.fr, accessed on 
day/month/year. 
 
 
In Sweden the 2013 incidence translates to 468 cases of cancer and 180 cancer deaths, 
a survival rate of 73% (socialstyrelsen.se, 2013). The worse prognosis seen in 
developing countries is associated with limited availability of hospital resources and 
women waiting too long to seek medical care. This disease was first described by 
Rigoni-Stern in 1842 (Rigoni-Stern, 1842) who also observed that cxca is related to 
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sexual activity and reproduction. Many risk factors for cervical cancer have been 
demonstrated, including early sexual debut, higher number of sexual partners, smoking 
and long-term use of oral contraceptives (Louie et al., 2009; Shavit, Roura, Barchana, 
Diaz, & Bornstein, 2013). A low incidence can be found among nuns (Fraumeni, Lloyd, 
Smith, & Wagoner, 1969) and women without a sexual partner (Fraumeni, et al., 1969). 
Studies have also shown that male circumcision reduces the incidence (Gray et al.) even 
when multiple partners are involved (Castellsague et al., 2006). Thus, development of 
cxca is strongly related to environmental factors and lifestyle, early sexual debut and 
multiple partners as key risk factors. 
 
 
3.3. HISTOLOGICAL CLASSIFICATION 
In 1968, a new histological classification of precursor lesions was developed, 
designated Cervical Intraepithelial Neoplasia (CIN). The term CIN implies a neoplastic 
lesion without specifying degree of severity (Barron & Richart, 1968; Fu, Reagan, & 
Richart, 1981). The classification includes evaluation of epithelial maturation. Thus in 
CIN1 (Grade 1), the least severe degree of cellular change, the border between the 
parabasal and intermediate squamous cells is still visible in the basal third of the 
epithelium. Such lesions are often difficult to differentiate from reactive changes. In 
CIN2, atypical parabasal cells are found in the middle third of the epithelium, whereas 
in CIN3, equivalent to carcinoma-in-situ (CIS), they occupy more than two-thirds of 
the total epithelial thickness. Histopathology serves as the gold standard for quality 
control of cytology and colposcopy. 
 
 
3.4 CYTOLOGICAL CLASSIFICATION 
In 1988, a working group at the National Cancer Institute (Bethesda, USA) introduced 
the Bethesda system for cervical/vaginal cytological diagnoses (Solomon et al., 2002). 
The goal was to provide uniform diagnostic terminology to facilitate communication 
between laboratory and clinician. This Bethesda system allowed for modification of 
classification if necessary and was duly revised in 2001 in response to new technologies 
and findings. The Europe Against Cancer Program introduced European guidelines for 
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quality assurance in cervical cancer screening The recommendation was for cytology 
laboratories to apply a national cytology terminology with uniform grading of cellular 
abnormalities, in parallel with the Bethesda reporting system. 
 
The current Swedish classification system can be translated into classification 
according to the 2001 Bethesda system. However, one difference is that samples with 
koilocytosis without cellular atypia are reported as within normal limits (WNL) in 
Sweden. Low-grade lesions include atypical squamous cells of undetermined 
significance (ASCUS) and CIN1. Squamous cell changes classified as high-grade 
squamous intraepithelial lesions (HSIL) are graded as CIN2 or CIN3. Cell changes that 
raise suspicion of an HSIL lesion are grouped as ASC-H (atypical squamous cells, favor 
high-grade lesion). Adenocarcinoma in situ (AIS) and adenocarcinoma (ADCA) 
represent about 20% of all cervical cancers (Gien, Beauchemin, & Thomas, 2010). The 
Bethesda system discriminates between atypical glandular cells of undetermined 
significance (AGUS), atypical glandular cells, favor neoplastic, AIS and ADCA 
(Solomon, et al., 2002). 
 
The information of sample adequacy as an important part of the cytology report has 
been a contributions of TBS. The guidelines constitute the adequacy of the sample for 
the detection of abnormalities of the uterine cervix: (i) patient and sample identification, 
(ii) relevant clinical information, (iii) adequate number of well-preserved epithelial cells 
(iiii) cellular composition and sampling of the transformation zone. The Bethesda 
system defines a fully satisfactory sample as containing both squamous cells and 
endocervical or squamous metaplastic cells. These cellular component form the 
microscopic basis that the TZ has been sampled (Kurman, Henson, Herbst, Noller, & 
Schiffman, 1994). 
 
3.4.1. SAMPLING 
Pap smear cytology, which is recommended by the WHO and still in use, involves 
collecting exfoliated cells from the ectocervix and endocervix, and in some areas from 
the fornix. The best sampling tools are a combination of a wooden spatula (Ayre or 
Aylesbury) and an endocervical brush, (Cytobrush) (Arbyn et al., 2007), but other 
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sampling devices are also available, including a broom-like device (Bigras et al., 2003). 
The cells from each tool are smeared on separate glass slides and immediately fixed in 
95% ethanol to prevent air-drying artifacts, which should be carefully avoided since 
they affect staining and the texture of nuclei and cytoplasm. After fixation the slides 
can be dried without risk of inducing artifacts that interfere with subsequent 
Papanicolaou staining. 
Liquid-based cytology (LBC) is an alternative method that was developed to improve 
sampling (Figure 5). Today, this method is becoming common, especially in many 
countries with a high economic standard. Two general techniques are available: 
ThinPrep® (TP) (Hologic, Marlborough, MA, USA) and SurePath™ (BD, Franklin 
Lakes, NJ, USA). The US Food and Drug Administration (FDA) approved SurePath™ 
in 2004 and the TP test in 1996, based on split-sample analysis (Limaye, Connor, 
Huang, & Luff, 2003). 
 
   
Pap smear   LBC 
 
Figure 5. Squamous cells with high grade lesions seen in the conventional Pap smear and in 
an LBC sample  
 
LBC technique involves obtaining samples using either a broom-like device or the 
combination of an endocervical brush and plastic spatula, after which the cells are 
directly stirred into a vial containing buffered fixative solution. The LBC sample is 
stored in this fixative until further processing in the laboratory. LBC enables more rapid 
fixation. The fixative contains hemolytic and proteolytic agents that separate epithelial 
cells from blood and mucus during filtration. In the TP technique, the cells are then 
collected on a filter membrane, after which they are transferred to a glass slide using an 
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automated TP Processor. This sample preparation method produces an almost single 
layer of cells without drying artifacts.  
 
   
Pap smear       LBC 
 
Figure 6. Squamous cells are easily demonstrated in the LBC sample, while they in the Pap-
smear are hidden under a curtain of inflammatory cells 
 
This technique is superior for preserving morphology (Figure 6), while making the 
remaining cell suspension available for supplementary analyses to improve test 
performance. (Obwegeser & Brack, 2001; Park, Jung, Kim, & Choi, 2007; Ronco et al., 
2007; Schledermann, Ejersbo, & Hoelund, 2006). The thin uniform layer of well-
preserved cells facilitates microscopic interpretation. This method can be used to 
improve screening program performance. (Strander, Andersson-Ellstrom, Milsom, 
Radberg, & Ryd, 2007; Tsonev, Ivanov, Kovachev, Kornovski, & Ismail, 2013; Zhu et 
al., 2007). Other studies have failed to demonstrate any significant difference between 
LBC and conventional cytology (Arbyn et al., 2008; Froberg et al., 2013; Siebers et al., 
2009; Tsonev, et al., 2013). At the time the second study was being conducted, LBC 
and HPV testing were new laboratory techniques, for which reason the learning curve 
may have influenced the results. Thus one advantage of LBC is that a significant portion 
of the sample remains after processing, which allows for adjuvant analysis to increase 
specificity. Such adjuvant analyses may include testing for high-risk human 
papillomavirus (HR-HPV), or immunocytochemistry to identify possible progression 
and diagnostic markers, both of which may facilitate distinguishing premalignant 
lesions from reactive changes (Bergeron et al., 2014). 
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3.4.2. STAINING 
The staining protocol for both conventional and LBC samples is polychromatic using 
one nuclear staining dye, acidified Harris Hematoxylin (HTX), and two counterstains, 
Orange G-6 (OG) and Eosin Azure-50 (EA) (G. N. Papanicolaou, 1942). To obtain a 
better chromatin pattern HTX stains the nucleus a crisp blue. This dye binds to 
chromatin-associated proteins (histones and other structures), rather than to the nucleic 
acid itself (Frost, 1997). OG-6 counterstain is an acidic dye that stains superficial 
squamous cells an intense orange to yellow color, as it binds to keratin and glycogen. 
EA-50 is in itself a polychromatic staining solution, containing light green SF and eosin 
Y that stain several cellular components. This dye therefore colors the cytoplasm of 
intermediate and parabasal cells, resulting in both a pink and a turquoise-green-to-blue 
appearance (Boon, 1996; Keebler, 1997) 
 
 
 
3.5. CYTOMORPHOLOGY. CRITERIA FOR EPITHELIAL CELL ABNORMALITIES 
 
3.5.1. ASCUS means that it cannot be decided if the lesion is a precancerous one, hence 
the term “undetermined significance”. The nuclear enlargement is two and a half to 
three times that of a normal intermediate squamous cell. Variation in nuclear size, shape 
and binucleation may be observed. Mild hyperchromasia may be present, but evenly 
distributed without granularity. Nuclear outlines usually smooth and regular.  
 
3.5.2. Low-grade squamous lesion (LSIL) is classified as cellular changes associated 
with koilocytosis, with or without simultaneous mild dysplasia/CIN1. Nuclear 
abnormalities are generally confined to cells with intermediate or superficial cell 
cytoplasm. The nuclear are enlarged at least three times compare to normal intermediate 
nuclei, with correspondingly increased nuclear/cytoplasmic (N/C) ratio. The chromatin 
is evenly distributed but slightly coarse and the nuclear membranes are slightly 
irregular. A moderate variation in nuclear size is often present. Nucleoli are rarely 
presents. To avoid confusion with molecular tests for HPV, it is required in Sweden that 
koilocytosis without nuclear atypia is reported as WNL. 
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3.5.3. High-grade squamous lesion (HSIL) includes changes associated with moderate 
dysplasia/CIN2 and severe dysplasia CIN3/CIS. The cells usually show predominant 
nuclear abnormalities, including nuclear irregularities, folding and hyperchromasia 
with coarsely granular chromatin without macronucleoli. The nuclei are not larger than 
in LSIL but the cytoplasm is decreased leading to increased N/C ratio. The main criteria 
separating HSIL into CIN2 or CIN3/CIS are the N/C ratio and tendency to dissociate. 
In CIN3/SIC lesion the abnormal cells also occur singly, often in the form of more or 
less naked nuclei (“grapes”). 
 
3.5.4. In non-keratinizing squamous cell carcinoma (SCC) the cells occur singly or 
in syncytial-like aggregates. They have all the features of HSIL together with prominent 
macronucleoli and irregular distribution of chromatin. The SCC often has an associated 
tumor diathesis with necrotic debris and old blood.  
 
3.5.5. In keratinizing SCC the cells occurs more often singly and less commonly in 
aggregates. There is a more prominent polymorphism with cells showing orangeophilic 
cytoplasm. Nuclei vary markedly in size, macronucleoli being less common than in the 
non-keratinizing tumor.  
 
3.5.6. Adenocarcinoma in situ (AIS) presents with groups and strips of cells, rosette 
formation, feathering, crowding and/or pseudostratification. The cells show increased 
N/C ratio with fine to coarsely granular chromatin, evenly distributed and most often 
hyperchromatic with prominent nucleoli. 
Cells from a cervical adenocarcinoma occur in 2- and 3-dimensional clusters and 
sheets, sometimes with finely vacuolated cytoplasm. Round to oval enlarged nuclei 
with fine to coarsely granular patterns. There is parachromatin clearing and irregular 
nucleoli are often prominent and multiple. 
 
The major microscopic differences between the Pap smear and the LBC sample are the 
cellular distribution and cell preservation. The Pap smear has thick and thin areas with 
artifacts after the mechanical distortion of the cell material. In LBC samples, the cells 
 24 
are well preserved due to immediate fixation and the preparation is uniform with evenly 
distributed cells. The LBC sample is almost monolayer with less overlapping cells.  
The nuclear hyperchromasia associated with squamous lesions in the Pap smear may 
be less extensive in LBC samples, but the nuclear morphology is enhanced, primarily 
as the result of the immediate LBC fixation. Another feature of the fixation, the cell in 
LBC samples tend to round up and be smaller in liquid-based preparation. 
 
Many of the low grade lesions seen in LBC samples cannot be recognized in 
conventional smears, explaining why LBC can be conducted with high sensitivity, 
improving the sensitivity and preserving the specificity by reflex analysis of HPV DNA. 
Nuclei may, however, be over-interpreted and it is important to carefully evaluate the 
nucleus under high power, especially in the absence of hyperchromasia. 
 
In general, the LBC cell pattern is similar to what is observed on well-preserved Pap 
smear. However, unlike the Pap smear, the background in LBC is generally clean and 
single cells are more prominent. The presence of blood, inflammation and diathesis is 
less apparent compared to the conventional Pap smear. The ability to recognize the 
tumor diathesis is essential when considering a malignant process in the LBC samples. 
 
 
3.6. HUMAN PAPILLOMAVIRUS 
3.6.1. HPV classification 
Papillomaviruses (PVs) belong to the Papovaviridae family. Almost 200 different HPV 
types, belonging to 49 species, have been characterized (WWW.hpvcenter.se, accessed 
on 2014-11-25) and modern sequencing techniques will continue to add new types 
(Arroyo Muhr et al., 2014; Bzhalava, Eklund, & Dillner, 2015; Eklund, Forslund, 
Wallin, & Dillner, 2014). HPV virus is highly species-specific, does not change host, 
and has been genomically stable for millions of years. 
PV nomenclature is established by the International Committee on Taxonomy of 
Viruses (ICTV) based on the Study Group of Papillomavirus (Bernard et al., 2010; Z. 
Chen, de Freitas, & Burk, 2015; de Villiers, Fauquet, Broker, Bernard, & zur Hausen, 
2004). Different PVs infect mammals and birds. The viruses are classified according to 
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taxonomic levels: genus, species, type, subtype and variant (Bzhalava, et al., 2015). PV 
form five major genera: Alpha-papillomavirus, Beta-papillomavirus, Gamma-
papillomavirus, Mu-papillomavirus and Nu-papillomavirus. Different genera have less 
than 60% similarity within the L1 genome. Species within a genus share about 60-70% 
nucleotide similarity and newly isolated HPV types must be at least 10% different from 
any other known HPV type. Subtypes differ by 2-10% and variants by <2% when 
compared with the most similar known HPV type (Bernard, et al., 2010). 
 
Alpha-papillomaviruses are divided into two groups: cutaneous and mucosal. The 
genital mucosal alpha genus has been studied most because it contains the viruses that 
cause cxca (Doorbar, 2013). Today, novel HPV types are assigned a number after the 
whole genome has been cloned and sent to the International HPV Reference Center 
(Bernard, et al., 2010; de Villiers, et al., 2004). Currently about 40 different HPV types 
have been find to infect genital epithelium. Mucosal types are subdivided into high-risk 
(HR) and low-risk (LR), based on oncogenic potential (Bernard, et al., 2010). LR-
HPVs, such as types 6 and 11, are mainly associated with benign genital warts, while 
HR-HPVs are carcinogenic agents for cxca. 
 
In 2012, the International Agency for Research on Cancer (IARC) concluded that there 
was consistent and sufficient epidemiological, experimental and mechanistic evidence 
for carcinogenicity in 12 HR-HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
and HPV59) ("Biological agents. Volume 100 B. A review of human carcinogens," 
2012). All of them belong to the α-Papillomavirus family and are considered to be 1A 
carcinogens. Lesser evidence is available for a thirteenth agent, HPV68, which is 
classified as a 2A carcinogen. In one recent study, 96% of evaluated cancer cases could 
be attributed to one of the 13 HR-HPV types. 
 
In light of additional data (Halec et al., 2014; Halec et al., 2013), evidence indicates that 
an upgrading of HR-HPV types could be considered. To specify numbers to new HPV 
types, an international HPV center was established at the German Cancer Research 
Center in 1985 (Bernard, et al., 2010; de Villiers, 2013). This International HPV 
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Reference Center stores reference clones and distributes samples to researchers. In 
2012, this center was transferred to Karolinska Institutet at Huddinge. 
 
 
3.6.2. HPV genome 
HPVs are small double-stranded circular DNA viruses with about 8000 base pairs. The 
genome of HPV16, the most studied type, is organized into three different regions: (i) 
early (E) genes (E1, E2, E4,E5, E6 and E7), (ii) a region containing two late (L) genes 
that encode the major L1 and the minor L2 capsid proteins, and (iii) the long control 
region (LCR), located between L1 and E6 (Bernard, et al., 2010). 
 
HR-HPV E6 and E7 are viral oncogenes that play a key role in carcinogenesis by 
transforming and immortalizing cells. E6 is able to inactivate the p53 tumor suppressor  
protein, thereby interfering with DNA repair and apoptosis. The primary target of E7 is 
the pRb tumor suppressor protein that both controls transcription factor E2F and exerts 
negative  
regulatory control on the G0/G1 phase of the cell cycle. E7 may induce abnormal cell 
proliferation by inactivation of pRb, which ultimately results in failure to prevent cells 
with  
damaged DNA from entering into s-phase and undergoing subsequent mitosis.  
This process creates a less stable genome with increased risk of mutations (Doorbar, et 
al., 2012; M. Stanley, 2010; M. A. Stanley, 2012) (Moody & Laimins, 2010; 
Tommasino, 2014). 
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Figure 7. The HPV genome of HPV16. Functions in early (E) and late (L) regions. 
 
 
 
3.6.3. The HPV infection 
Genital warts have been known since antiquity. Even in ancient Rome the link between 
sexual activity and the presence of such warts was noted. Genital wart infection as a 
consequence of sexually transmitted infection was only confirmed in the twentieth 
century. In 1907, Ciuffo (Ciuffo, 1907) showed that human skin warts contained an 
infectious substance, identified as a submicroscopic organism. In 1935, Rous and Beard 
demonstrated that the virus could induce papillomas in rabbits (Rous & Beard, 1935), 
which was eventually confirmed by Stauss et al., 1949, who visualized the viral particles 
in wart extracts, using electron microscopy (Strauss, Shaw, & et al., 1949). 
 
The suspicion that cxca can be caused by an infectious agent was first raised in the 
1840s (Rigoni-Stern, 1842). In the late 1960s, this form of cancer was associated at first 
with Herpes Simplex Virus 2 (HSV2) (Goldberg & Gravell, 1976). However, in the 
1970s, this hypothesis was abandoned (Lehtinen et al., 1992; Lehtinen et al., 1989), and 
E1: Mainly controls viral DNA replication 
E2: Responsible for gene transcription and viral replication 
E4: Mediates virion particle release by destabilizing keratin in the 
cytoskeleton 
E5: Stimulates growth factors through inhibition of apoptosis 
E6: Inactivates p53-dependent apoptosis 
E7: Inactivates members of the pRb family of tumor suppressor proteins 
by promoting cell cycle progression  
L1: Assembly of capsomeres from viral genome 
L2: Works together with L1 on assembly of viral capsid; participates in 
viral entry process of infection 
(Bosch et al., 2013; Moody & Laimins, 2010) 
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the focus shifted to findings which showed that HPV played a central role in the 
development of cxca (J. zur Hausen, Schulte-Holthausen, Wolf, Dorries, & Egger, 
1974)). The causative role of HR-HPV for the development of cxca was subsequently 
established (H. zur Hausen, 1977, 1998, 2009). In 1983 HPV16 was identified in cxca 
biopsies (Durst, Gissmann, Ikenberg, & zur Hausen, 1983), and by the next decade both 
HPV 16 and HPV 17 had been cloned. These two HPV types are found in approximately 
70% of cxca cases worldwide (J. S. Smith et al., 2007). In 2008 Harald zur Hausen was 
awarded the Nobel Prize in Physiology or Medicine, for his role in the discovery that 
HPV is the causal agent of cancers. 
 
HPV infection is one of the most common sexually transmitted infections in the world 
(M. Stanley, 2010). Nearly 100% of all cervical cancers contain HR-HPV DNA (Bosch 
et al., 1995; Munoz et al., 2003; J. S. Smith, et al., 2007). Persistent infection with HPV 
is a prerequisite in almost every case of cervical cancer, but is insufficient as a sole 
agent to cause cervical cancer (Walboomers et al., 1999). HPV infection increases the 
risk for developing cancer in a multistep process (Schiffman, et al., 2007). 
 
Lifetime risk of HPV infection has been estimated at about 80% (Koutsky, 1997) 
depending on various cultural factors. Time from infection to release of complete viral 
particles is about two-three weeks (M. A. Stanley, 2012). However, the majority of HR-
HPV infections are transient and clear spontaneously within six to twelve months 
(Doorbar, 2006; H. zur Hausen, 2009). Global HPV prevalence is about 10%, albeit 
with great variation. Prevalence is low in Eastern Asia (6%), but high in Eastern Africa 
(31%). In Northern Europe it is estimated at about 7%, with large differences among 
age groups ((Ferlay, et al., 2015; Wahlstrom, Iftner, Dillner, & Dillner, 2007). 
 
It is estimated that some 10% of sexually active women, with normal cervical cytology, 
are at risk of developing persistent infection (de Sanjose et al., 2007). These women 
represent a high-risk group for initiation of a pathological process with progression to 
precancerous and invasive cancer lesions. In addition, smoking, sexual habits, parity, 
oral contraceptives and genetic factors have all been associated with increased risk 
((Moreno et al., 2002; Moreno et al., 1995; Munoz et al., 2002). 
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Figure 8. Squamous cells with high grade lesions. 
 
 
 
 
3.6.4. Onset of infection 
HPV infects basal cells, usually at the site of the transformation zone with its squamo-
columnar junction; less commonly, the virus enters through a microscopic wound 
elsewhere in the epithelium. Studies have shown that the viral capsid protein L1 binds 
to syndecan-1, the heparan sulfate proteoglycan, which acts as the receptor to internalize 
the viral particle (Horvath, Boulet, Renoux, Delvenne, & Bogers, 2010; Johnson et al., 
2009; Joyce et al., 1999). Other studies have shown that the minor capsid protein L2 
also participates in this process of binding to the cell membrane (Bergant & Banks, 
2013; Woodham et al., 2012). Production of virions depends on differentiated 
superficial epithelial cells, where L1 and L2 capsid proteins are produced. 
 
The virus infects basal cells as the primary target; after 12-24 hours (Maglennon, 
McIntosh, & Doorbar, 2011) replication produces about 200 viral DNA copies per cell. 
The infected cells enter a phase of episomal maintenance, during which time 
transcription from the two early genes, E6 and E7, is hardly measurable. Once the 
infected keratinocyte begins to differentiate, expression of E6 and E7 is high. When the 
cell exits the cell cycle, viral DNA replication continues, with amplification resulting 
in at least 1000 viral copies per cell. The primary cycle of infection is complete, after at 
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least 3 weeks, when the L1 and L2 capsid proteins are expressed in the upper epithelial 
layer, allowing the assembly and release of complete virions at the epithelial surface 
(M. Stanley, 2010). The function of E6 and E7 is to activate DNA synthesis during 
replication by interfering with the two tumor suppressor proteins, p53 and 
retinoblastoma protein (pRb) (Dyson et al., 1989). E6 protein increases degradation of 
p53, while E7 protein irreversibly phosphorylates pRb, thereby inactivating it and 
causing a release of transcription factor E2F.Since the two tumor suppressor proteins, 
p53 and pRb, function as “guardians of the genome,” long-term infection with HR-HPV 
may eventually affect cellular genetic stability by increasing the likelihood of survival 
for mutated cells. E6 and E7 also play a major role in carcinogenesis through evasion 
and downregulation of the innate immune response. The ability of the virus to evade 
the immune system is a prerequisite for tumorigenesis. (Tindle, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. p16INK4a in normal cell. With permission from Dako Sweden. 
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3.6.5. Morphological changes due to HPV infection 
 
 
Figure 10. Koilocytes. Mature squamous epithelial cell with a perinuclear cytoplasmic 
halo. 
 
Indications of HPV infection may be ascertained from both cytological and histological 
samples. The most characteristic cytological finding of HPV is koilocytosis. The 
koilocyte is a mature squamous epithelial cell with a large perinuclear cytoplasmic halo. 
The halo may be irregular and surrounded by a dense cytoplasmic zone. (Frost, 1997; 
Papanicolaou, 1960). In 1976-77, two separate studies described the koilocyte as the 
most characteristic cytological feature of HPV infection (Meisels & Fortin, 1976; 
Meisels, Morin, Casas-Cordero, Roy, & Fortier, 1981; Meisels et al., 1981; Purola & 
Savia, 1977). Indeed, this finding represents a fixation artifact resulting from the effects 
of HPV on the cytoskeleton and shrinkage during dehydration; in cytology it is a strong 
indicator of HPV infection (Tanaka, Chua, Lindh, & Hjerpe, 1993). 
 
 
3.6.6. HPV vaccines 
Prophylactic HPV vaccines were developed to prevent HPV infections. Two such 
licensed HPV vaccines are currently available. The first, Gardasil® (Merck & Co, 
Whitehouse Station, NJ, USA), is a quadrivalent vaccine based on virus-like particles 
(VLP) from types 6, 11, 16 and 18, while the second, Cervarix® (GlaxoSmithKline 
Biologicals, Rixensart, Belgium) is bivalent, containing only VLPs from types 16 and 
18. Both were approved for use in the US, Europe and Australia in 2006. Studies have 
shown almost complete protection against HPV infection from the types found in the 
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respective vaccines. The HPV vaccines are expected to provide more than 50% 
protection against ICC (B. Lu, Kumar, Castellsague, & Giuliano, 2011; "Quadrivalent 
vaccine against human papillomavirus to prevent high-grade cervical lesions," 2007). 
A study recently showed a decreased risk for condyloma after two of three doses of 
vaccine (Herweijer et al., 2014). Therapeutic effects on established CIN lesions have 
not been found. 
 
A nine-valent vaccine containing HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 has 
been tested and is expected to provide 90% protection against ICC. (Serrano et al., 
2014). However, this vaccine is not yet commercially available. The antibodies 
produced against HPV virus are present in the secretions covering the cervical canal, 
squamocolumnar junction and vagina, which is believed to contribute to the vaccine-
mediated neutralization of the virus. In this way the vaccine may protect against 
infection in the cervix and vagina, but not on dry surfaces such as the vulva and penis. 
(M. A. Stanley, 2012). 
 
 
3.7. CANCER PREVENTION 
3.7.1 Cytology 
Carcinoma develops over an extended period of time, 10-20 years (H. C. Chen et al., 
2011; McCredie et al., 2008), with premalignant stages that can be detected by cytology. 
(Echelman & Feldman, 2012; Russell, Raheja, & Jaiyesimi, 2013; Schmitt et al., 2013). 
Mortality in cxca has decreased in countries that have implemented a population-based 
cervical cytology screening program (Gustafsson & Adami, 1989; Gustafsson, Ponten, 
Bergstrom, & Adami, 1997). The main goal of population-based cervical screening is 
to reduce incidence and mortality from cervical cancer. The aim is detection and 
treatment of early lesions while they are still precancerous. This slow carcinogenic 
process meets the WHO criteria for mass screening using the Pap smear, Papanicolaou 
test, Pap test, or cervical smear, (G. N. Papanicolaou, 1942; G. N. Papanicolaou & 
Traut, 1997; Papanicolau GN, 1941) a comparatively simple and cost-effective 
approach. The Cytopathologist and innovater, father of cytology, Dr. George 
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Papanicolaou was first to introduce the Pap smear in the 1920s. It was through Dr 
Papanicolaou´s effort that cytology became accepted as a diagnostic method. 
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Figure 11. Incidence och mortality of cxca in Sweden. With permission from Pär Sparén, 
Karolinska Institutet, Sweden. 
 
 
Sweden first offered primary cytology screening programs for cervical cancer in 
Stockholm in 1967, and the program was recommended for nationwide implementation 
in 1973, using the conventional Pap smear (Socialstyrelsen.se, 1998). The program 
initially encompassed women aged 30 to 49, with a four-year sampling interval 
(Pettersson, Bjorkholm, & Naslund, 1985). At that time the oncogenic mechanisms 
were not yet well understood and the incidence of cxca exceeded 800 cases per year. 
The current recommendation in Sweden is to call women aged 23-49 for sampling every 
3 years and women aged 50-60 every 5 years. (Socialstyrelsen.se, 1998). 
 
A recent audit indicates that the screening program has been effective (Figure 11). Since 
its inception, the incidence of cervical squamous cell carcinoma (SCC) has decreased 
considerably (Bergstrom, Sparen, & Adami, 1999; Gunnell et al., 2007). It is important 
that the program reach the at-risk population, especially women older than 35 years. 
The majority of women diagnosed with advanced-stage invasive cxca have never 
participated in the screening program (Bos, Rebolj, Habbema, & van Ballegooijen, 
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2006; Rozemeijer et al., 2014). Reliability in cytological screening is dependent on 
repeated sampling; thus some cancers will develop despite previously normal screening 
results (Andersson-Ellstrom, Seidal, Grannas, & Hagmar, 2000; Andrae & Strander, 
2000). 
 
A prospective cohort study (n=1230) of all cervical cancers 1999-2001 showed that 
invasive cxca detected by screening had a better prognosis than cancer detected by 
symptoms (Andrae et al., 2012). Despite the encouraging results of the screening 
program, cxca is still responsible for many deaths (Hakama, 1993) (Andrae & Strander, 
2000). Pap test sensitivity may be limited by inadequate sampling with low cellularity, 
poor cell preservation or suboptimal sampling with insufficient yield from the 
transformation zone. Sampling error is the main factor responsible for low sensitivity 
and contributes to a large proportion of false negative results (Chamberlain, 1986; Dunn 
& Schweitzer, 1981; Gay, 1984). 
 
Annually, nearly 800,000 cytology samples are obtained in Sweden, with the largest 
laboratory reporting some type of change in 5-6% of these (Nationellt Kvalitetsregister 
för Cervixcancerprevention, 2014). This number is significantly larger than the number 
of women who would otherwise develop cxca. While women with precancerous 
changes are successfully identified, these analyses also initiate a follow-up process for 
a number of women who are not likely to develop cxca since minor changes may often 
be impossible to distinguish from true precancerous lesions.  
Thus the moderate specificity associated with Pap smears (Andrae et al., 2008) may 
cause unnecessary anxiety for the latter group of women and significant costs for 
society. (Ostensson, Froberg, Hjerpe, Zethraeus, & Andersson, 2010; Ostensson et al., 
2013). 
 
 
3.7.2. HPV-screening 
The organized cxca screening program has been successful, but several studies have 
shown that one single Pap test has a limited sensitivity, 50-70%, for detecting CIN 
(Andrae, et al., 2008; Dunn & Schweitzer, 1981). Today, the HPV testing is a 
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commonly used supplementary analysis to better separate reactive lesions from 
precancerous ones (Arbyn et al., 2012; Ronco et al., 2014). On the basis of the nearly 
100% link between HR-HPV and cxca, testing for HPV DNA is now being established. 
The sensitivity for detecting a premalignant or established malignant lesion at least 
correspondingly to CIN2 (CIN2+) or CIN3 (CIN3+) lesion is very high. HR-HPV is 
present in about 95% of samples with CIN2+, but the specificity is low (Cuzick et al., 
2006) (Arbyn et al., 2009; Franco, 2009). Around 60% of HPV positive women have 
no detectable lesion (Cuzick et al., 2003; Herbert, 2007).  
 
Today HPV testing is a commonly used supplementary analysis to help distinguish 
reactive lesions from precancerous lesions. In samples read as ASCUS, LSIL absence 
of HR-HPV indicates that the observed abnormality is unlikely to be precancerous 
(Kitchener, Denton, Soldan, & Crosbie, 2013; Naucler et al., 2007) and absence of HR-
HPV indicates that an observed abnormality is less probably precancerous. 
Furthermore, HPV testing is sensitive as a “test of cure” after treatment of CIN2+ 
lesions, (Arbyn et al., 2004; Arbyn, et al., 2012; Chua & Hjerpe, 1996). LBC has an 
advantage in that adjuvant HPV testing can be performed as a “reflex test” from residual 
sample material, without having to recall the patient. New generation of HPV tests may 
be more specific and may distinguish persistent from transient HPV infection, although 
this is not yet the case. Together, LBC and HPV can increase the sensitivity and 
specificity of the test. 
 
 
 
3.7.3. HPV testing in primary screening 
Studies have shown that, primary HPV screening can be effectively combined with 
cytology triage of HPV positive women (Kitchener, 2015; Kotaniemi-Talonen, 
Nieminen, Anttila, & Hakama, 2005). Moreover, some years later another study showed 
no different sensitivity in HPV and cytology screening (Kotaniemi-Talonen et al., 2007; 
Malila et al., 2013).  
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Lower costs for HPV testing today is another argument for primary screening 
(Bistoletti, Sennfalt, & Dillner, 2008; Ostensson, et al., 2010). Presence of unusual HR-
HPV types not detected with today’s commercial reagents will leave some cases 
undetected. Furthermore, studies have shown that HR-HPV screening can be as 
effective as cytology screening in reducing the incidence of precancerous abnormalities 
(Arbyn, et al., 2012; Ronco, et al., 2014). Several countries have or are in the process 
swiching to primary HR-HPV testing, however, the primary screening for HPV remains 
controversial.  
 
 
3.8. MOLECULAR MARKERS 
 
 
Figure 12. p16ink4a reactivity in HSIL sample. 
 
 
3.8.1. p16INK4a 
p16INK4a is a protein that acts as a cyclin-dependent kinase (CDK) inhibitor and cell-
cycle regulator; expression is normally strictly controlled. Expression of p16INK4a 
prevents pRb phosphorylation, E2F release and cell cycle progression. Free E2F also 
stimulates p16INK4a, which in turn leads to reduced phosphorylation of pRb and 
therefore increased binding and inactivation of E2F. Active pRb is phosphorylated by 
the CDK complex and the subsequent release of E2F allows the cell to progress from 
G1 to S-phase. In normal cells (Figure 9), p16INK4a influences cell proliferation via a 
negative feedback loop to downregulate CDK 4 and CDK 6. This downregulation leads 
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to cell cycle arrest with accumulation of inactive unphosphorylated pRb-E2F complex 
and less free E2F transcription factor (Stern et al., 2012). 
The effects of the E7 protein on pRb in the transformed cell are interaction and 
inactivation. E7 disrupts the inactive pRb-E2F protein complex, increasing free E2F, 
which in turn leads to binding of E7 to pRb protein (Figure 13). This degradation of 
pRb protein by E7 activates E2F transcription, resulting in increased free E2F which 
stimulates p16INK4a expression. Thus expression of E6 and E7 results in uncontrolled 
cell cycle progression without apoptosis, thereby increasing the risk for mutations. 
Therefore such expression is necessary for malignant transformation of the infected 
epithelium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. p16INK4a in oncogenic transformation. With permission from Dako Sweden. 
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Accumulation of p16INK4a in the nucleus (Figure 12) is a consequence of impaired pRb 
and has therefore been proposed for use as a biomarker to identify dysplastic cells (von 
Knebel Doeberitz, 2002). In normal cells, p16INK4a expression is either faint or 
undetectable by immunocytochemistry. Some immunoreactivity to this protein can be 
seen during cellular stress, such as in reactive conditions and repair situations. In LBC 
samples p16INK4 staining can be conducted for ancillary analysis, using leftover cell 
suspension. Immunocytochemical demonstration of p16 INK4a using conventional Pap 
smear counterstaining technique may improve our ability to distinguish between 
premalignant and reactive cellular stress. (Paper III) 
 
 
p16 INK4a / Ki-67 
A combination of p16 INK4a and Ki-67 is of interest for detection of exfoliated cells 
demonstrating simultaneous HPV transformation and proliferation. 
Immunocytochemical dual staining using the CINtec PLUS p16 INK4a /Ki-67 kit (Roche) 
can be performed on LBC samples. Studies have shown that this staining technique 
improves detection of CIN2+ on ASCUS and LSIL samples (Roelens et al., 2012; E. 
M. Smith, Rubenstein, Hoffman, Haugen, & Turek, 2010). Another study based on 
cytology negative and HR-HPV positive women have shown that the use of this dual 
staining cytology, when used as a reflex test, may identify the vast majority (<90%) of 
underlying HSIL (Petry et al., 2011). 
 
 
 
3.9.2. L1 capsid protein 
As previously mentioned, the major HPV L1 capsid protein is only produced during 
formation of HPV virions and only in the superficial squamous cell layer (Figure 13). 
The L1 and L2 capsid proteins are immunogenic and may, when released, initiate an 
immunological response.  
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Figure 13. HPV L1 reactivity only in the superficial squamous cell layer. 
 
 
 
Expression of this protein may indicate the possibility of spontaneous regression of the 
dysplastic lesion and the L1 protein may therefore serve as a prognostic marker. 
(Griesser, Sander, Hilfrich, Moser, & Schenck, 2004; Hilfrich & Hariri, 2008; 
Melsheimer, Kaul, Dobeck, & Bastert, 2003; Rauber, Mehlhorn, Fasching, Beckmann, 
& Ackermann, 2008), (Mehlhorn et al., 2014). The immune response to the L1 capsid 
protein (Figure 14), on which the available vaccines are based, may initiate clearance 
of the infection and prevent it from being persistent.  
 
 
 
 
Figure 14. Week to moderate L1 reactivity (left) and strong L1 reactivity (right). 
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Accordingly, absence of L1 expression may be one way by which infected cells are able 
to avoid the T cell-mediated immune response, which may result in persistent infection 
(M. Stanley, 2006). Studies have shown that immunocytochemical staining of the L1 
capsid protein may be valuable for predicting early precancerous lesions (Griesser, et 
al., 2004), (Hilfrich & Hariri, 2008). Furthermore, in another study of women with LSIL 
and HR-HPV, absence of L1 reactivity predicted both increased likelihood of 
progression and decreased likelihood of regression, compared with women in whom 
this protein was expressed. L1 reactivity has also been shown to have similar predictive 
value in CIN1 and CIN2 lesions (Rauber, et al., 2008). 
 
 
 
3.9.3. microRNA 
Recent advances in molecular biology and gene technology have opened up new 
opportunities to improve the yield of diagnostic information from sampled material. 
LBC samples are preferable when using these techniques. Many genetic alterations 
have been identified in cxca, but little is yet known about the role of microRNAs 
(miRNAs) in carcinogenesis. In most tumors, levels of many miRNAs are reduced, with 
the lowest levels found in the least differentiated tumors (J. Lu et al., 2005; Lui, 
Pourmand, Patterson, & Fire, 2007). MicroRNAs represent a family of short single-
stranded noncoding RNAs, with about 22 nucleotides. Many functions have been 
attributed to them.  
 
Experimental studies have shown that miRNAs are regulators of important biological 
processes such as cell proliferation, apoptosis, viral infection and cancer development 
(Bartel, 2004). Several studies have shown that miRNAs are aberrantly expressed or 
mutated in tumors and data strongly suggest that miRNA profiling is more robust than 
mRNA profiling with respect to tumor classification (Calin & Croce, 2006; Di Leva, 
Calin, & Croce, 2006; Garzon, Fabbri, Cimmino, Calin, & Croce, 2006). Studies have 
also shown that miRNA with altered expression has been identified in cxca when 
compared with normal cervical tissue (Huang et al., 2012; Lee et al., 2008; Lui, et al., 
2007; Martinez et al., 2008; Wang et al., 2009; Witten, Tibshirani, Gu, Fire, & Lui, 
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2010). In addition, a recent study confirmed that miR-205 expression was frequently 
higher in SCC than in normal cervical tissue (Xie, Zhao, Caramuta, Larsson, & Lui, 
2012). 
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2 4. AIMS 
 
4.1. GENERAL AIM 
The primary aim of this thesis is to explore what diagnostic information can be obtained 
from a single sample in the fields of cytology, virology and molecular biology using 
LBC. Would such a combination of analyses improve our ability to identify women at 
risk of developing cxca? 
 
4.2. SPECIFIC AIMS 
4.2.1. Paper I 
This split-sample study is designed to identify whether LBC provides higher sensitivity 
as a screening method for precancerous abnormalities compared with conventional Pap 
smear. 
 
4.2.2. Paper II 
The purpose of this study was to compare the combination of LBC plus HPV reflex 
testing in cases of minor cytological abnormalities (LBC+HPV testing) with 
conventional cytology (CC) in regard to their ability to identify precancerous lesions in 
a population-based screening setting.  
 
4.2.3. Paper III  
The aim of this study was to evaluate the use of immunocytochemical demonstration of 
p16 INK4a as a diagnostic marker in LBC samples and to assess the potential for this 
marker to distinguish between reactive and precancerous conditions. 
 
4.2.4. Paper IV 
The aim of this study was to evaluate the prognostic relevance of HPV L1 capsid protein 
expression and the presence of different HR-HPVs in LBC samples from women with 
minor cytological abnormalities. 
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4.2.5. Paper V 
The purpose of this study was to determine whether the level of miR-205 expression in 
LBC samples correlates with the presence of HR-HPV, histology and predicts 
progression. 
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3 5. MATERIAL AND METHODS 
 
5.1. ETHICAL PERMISSION 
All studies were approved by the regional Ethics Review Board in Stockholm and 
informed consent was obtained from all study subjects. 
Paper I. 04-679/3, Paper II. 04-679/3, Paper III. Dnr.04-679/3, 2010/944-32, 
Paper IV. Dnr.04-679/3, 2010/944-32, 
Paper V. Dnr.04-679/3, 2010/944-32, 2013/542-32 
 
5.2. STUDY DESIGN  
Paper I, II, III, IV, V 
LBC samples were obtained from the primary screening program, either as the primary 
sample or during secondary follow-up of abnormal findings within the program. The 
women were examined 2-6 months later at the Department of Gynecology and 
Obstetrics at Karolinska University Hospital Huddinge, Stockholm with pelvic 
examinations including cytology and histology sampling, colposcopy and biopsy. The 
cytology samples were independently evaluated, in accordance with the Swedish 
classification system, by different cytotechnologists and cytopathologists. The 
histological samples were assessed by a local pathologist and classified according to the 
WHO CIN classification, to be used as the gold standard. 
 
5.2.1. Paper I 
The study enrolled 137 women with any grade of cytological abnormality detected 
through the population-based cervical screening program in 2004. The split-sample 
study design allowed the performance of the two cytological methods to be evaluated 
through use of paired specimens. After first obtaining a conventional Pap smear, the 
remaining material was then rinsed in the LBC vial (ThinPrep®). 
 
5.2.2. Paper II 
After evaluating the diagnostic performance from the first study, Paper I, a total of 8320 
women from the population-based primary cervical screening program were invited to 
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participate in the study in 2005 and 2006. Six sampling centers in southern Stockholm 
participated in the study and the midwives involved had no influence on sample 
interpretation. Depending on the week of the appointment, either conventional Pap 
smear or LBC (ThinPrep®) samples were obtained and sampling technique was 
changed each week. In all, 4261 women were assigned to Pap smear and 4059 to LBC 
sampling. All women with any grade of abnormality were referred for colposcopy with 
pelvic examination, cytology resampling and histology sampling. In cases where low-
grade cytological abnormalities (ASCUS and LSIL) were found, supplementary HPV 
DNA testing was performed using LBC. Follow-up was undertaken on all women with 
abnormal cytology and test results were compared with histology and HPV testing 
within two years after the first cytology sampling. 
 
 
5.2.3. Paper III 
We consecutively enrolled 118 women with any grade of cytological abnormality 
detected through the population-based primary cervical screening program in 2004. In 
2005 these women were called for follow-up testing and immunocytochemical staining 
was performed with LBC samples and compared with the histological findings that 
served as the gold standard. 
 
5.2.4. Paper IV 
This study enrolled 112 women with minor cytological abnormalities detected through 
the population-based primary cervical screening program in southern Stockholm, 
Sweden between 2007 and 2009. All LBC samples were collected by midwives and 
prepared and evaluated at the Department of Clinical Pathology and Cytology at 
Karolinska University Hospital, Stockholm. Immunocytochemical staining for the HPV 
L1 capsid protein was performed according to manufacturer protocol and the results 
compared with the cytological and histological findings. 
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5.2.5. Paper V 
We enrolled 127 LBC samples classified as WNL, LSIL, HSIL , ICC that were obtained 
through a population-based primary cervical screening program in Stockholm and from 
the Department of Gynecology and Obstetrics at Karolinska University Hospital, 
Stockholm, between 2008 and 2011. The present study evaluated levels of miR-205 
expression and compared the findings with HPV type and histological lesion. 
 
5.3. PREPARATION OF CYTOLOGY SAMPLES 
Conventional Pap smear, (Papers I, II): The cells were collected from the fornix, 
ectocervix and endocervix using conventional Pap smear technique with a spatula and 
cervical brush. The cell sample was smeared into a glass slide and was immediately 
fixed in 95% ethanol, air-dried and stained according to protocol (G. N. Papanicolaou, 
1942) and interpreted by cytotechnologists. 
LBC, Papers I, II, III, IV, V: First a conventional Pap smear was obtained and the 
remaining material from spatula and brush was rinsed off into a vial with PreservCyt 
solution (ThinPrep®, Hologic, Marlborough, Ma USA). All LBC samples were 
prepared using a ThinPrep® 2000 processor (Hologic, Marlborough, Ma USA). All 
glass slides were stained according to a modified Pap protocol (more concentrated 
acetic acid) and evaluated by different cytotechnologists. Different individuals 
independently assessed the samples according to the Bethesda classification, modified 
to Swedish recommendations. 
 
5.4. HISTOLOGY 
In all Papers (I, II, III, IV, V) histological biopsies and cervical cones were performed 
using Zeiss OMPI colposcopy (Zeiss, Oberkochen, Germany) for magnification. The 
samples were preserved in 4% formaldehyde, analyzed according to the laboratory 
protocol and diagnosed and assessed by pathologists according to the CIN classification 
system ((Fu, et al., 1981). Histological results were retrieved from medical and 
laboratory records and from the Regional Cancer Center in Stockholm. 
 
5.5. HPV GENOTYPNING. (PAPERS. II, III, IV, V) 
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Linear Array HPV Genotyping: Papers II, III, IV. 
HPV DNA genotyping was performed on 2 ml of residual LBC cell suspension taken 
from LBC samples that showed ASCUS or LSIL. The cell suspension was centrifuged 
and lysed using the Total Nucleic Acid Isolation kit (Roche, Basel, Switzerland). DNA 
was extracted using the MagNA Pure LC Robot (Roche) and analyzed with the Linear 
Array HPV Genotyping Test (LA) (Roche) according to manufacture protocol. 
LA is a qualitative genotyping assay for 37 HPV types based on polymerase chain 
reaction (PCR) and probe hybridization. There are 12 HR-HPV types: HPV16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, and 59; six probable HR-HPV (pHR-HPV) types: HPV26, 
53, 66, 68, 73, and 82; and 19 LR-HPV types: HPV6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 
69, 70, 71, 72, 81, 83, 84, IS39, and CP6108. The LA test uses biotinylated primers 
during amplification of a 450 bp region on the HPV L1 gene, using a 268 bp region on 
human beta globin as a control. 
 
 
PapilloCheck® HPV Test. Paper V 
The PapilloCheck® HPV Screening test (greiner-bio-one), which is based on 
detection and genotyping of a sequence of the viral E1 gene, can identify 24 types of 
papillomavirus. The analysis is capable of showing the presence of 18 HR-HPV types 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82) and six LR-HPV 
types (6, 11, 40, 42, 43, 44). The DNA was extracted using the PapilloCheck® HPV 
Extraction Kit, and a 350 bp fragment of the E1 gene was obtained with multiplex-PCR. 
The human “housekeeping gene” ADAT1 (Adenosine deaminase tRNA-specific1) was 
used to show the presence of intact DNA. The amplification products were hybridized 
to specific probes attached to the chip. During hybridization, the bound DNA was 
fluorescently labelled and unbound DNA removed by washing. Finally, the 
PapilloCheck® DNA-chip was automatically scanned, analyzed and evaluated using 
the CheckScanner™ and CheckReport™Software respectively. 
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5.6. IMMUNOCYTOCHEMISTRY 
 
In Papers II and IV, extra slides from the remaining LBC sample were prepared for 
immunocytochemical staining according to manufacturer protocol. 
 
5.6.1. p16 INK4a (Paper III) 
The slides were post-fixed in acetone (PA) for 10 minutes at room temperature and air-
dried at least 30 minutes prior to immunostaining. All slides were subjected to antigen 
“Heat Induced Epitope Retrieval” (HIER) using Epitope Retrieval Solution (Dako, 
Copenhagen, Denmark) at 95º-100ºC for 10 minutes with Tris/EDTA buffer pH9. 
Immediately thereafter, the Coplin was removed from the water bath and left at room 
temperature for at least 20 minutes, followed by washing in diluted wash buffer 
(DakoCytomation) for 5 minutes. p16 INK4a staining was performed with the 
DakoCytomation Autostainer using the CINtec™ p16 INK4a Cytology Kit K5339, (Dako 
Cytomation, Glostrup, Denmark), according to the DakoCytomation protocol. 
 
For each staining, at least one positive and one negative control was used. 
Counterstaining was performed according to the Papanicolaou protocol using the 
LEIKA ST4040 automatic staining machine. Staining does not interfere with the 
immunocytochemistry, making it possible to simultaneously assess both dysplasia and 
p16 INK4a reactivity. The slides were analyzed by light microscopy and independently 
assessed by 2 people. p16 INK4a nuclear reactivity was considered to be negative (-) if 
fewer than three cells per slide showed reactivity (Bibbo, Klump, DeCecco, & 
Kovatich, 2002). Intensity of nuclear staining was evaluated according to increasing 
p16 INK4a reactivity (+, ++, +++). 
 
 
5.6.2. HPV L1 capsid protein (Paper IV) 
HPV L1 staining was carried out using the specific monoclonal antibody, Cytoactive®, 
(Cytoimmun, Diagnostics GmbH, Pirmasens, Germany) according to manufacturer´s 
protocol. The slides were fixed in 96% ethanol for 20 minutes, air-dried and stored at 
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room temperature until immunostaining was carried out. Antigen retrieval was 
performed using microwave treatment in Citrate buffer pH6 for 20 minutes. The 
Cytoactive® screening antibody was directly added to the slides and incubated at room 
temperature. The slides were then counterstained with HTX and L1 reactivity was 
independently assessed by different people. Slides in which at least one cell showed 
nuclear L1 reactivity (Griesser, et al., 2004)  were scored as positive. 
 
 
5.7. QUANTITATIVE REVERSE TRANSCRIPTION PCR (QRT-PCR) 
 
MicroRNA extraction. The microRNA study was carried out using 2 ml of residual cell 
suspension from each LBC sample. miRNA extraction was carried out using the 
mirVana™ miRNA isolation kit (Applied Biosystem/Ambion, Austin, TX, USA), 
applying small RNA enrichment from the LBC samples. Isolated miRNA concentration 
was measured with a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). 
Reverse transcription: For mature miRNA, total RNA was reverse-transcribed to 
cDNA using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). 
The Reverse Transcription Reaction Master Mix was prepared for the target miRNA 
and the endogenous control RNU6B. 
qRT-PCR: qRT-PCR reactions were performed in triplicate and expression of mature 
miRNA was quantified using the Applied Biosystems 7500 Fast Real-time PCR system 
(Applied Biosystems). 
 
  
 50 
5.8. STATISTICAL ANALYSES 
 
Data were analyzed with Statistica software (Statsoft® Inc, Tulsa, OK, USA). SAS® 
System 9.1 (SAS Institute Inc., Cary, NC, USA) software was used. 
 
5.8.1. Paper I 
The Chi-square (Chi²) statistic was calculated to test the significance of the data. All 
statistical tests were two-sided and the null hypothesis of difference was rejected at a 
significance level of p<0.05 
 
5.8.2. Paper II 
Logistic regression was used to assess the rates of CIN detection and of abnormal 
cytology in both the LBC-HPV triage group and the conventional cytology group. 
Results were presented as odds ratios (OR) and 95% confidence intervals (CI). A 
multivariate logistic regression model was computed including potential confounders. 
The times when analyses were undertaken were included to account for possible 
differences related to the learning curve associated with LBC. 
 
5.8.3. Paper III 
The chi-square test and Spearman rank-order correlation test were used to analyze 
results from immunocytochemical staining and CIN grading. Cytological and 
histological outcomes were computed to include sensitivity, specificity, positive and 
negative predictive value. 
 
5.8.4. Paper IV 
 
Data were analyzed using frequency count and percentages. The chi-square test was 
used to analyze the association between L1 capsid protein expression, different HR-
HPV types and CIN grade.  
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5.8.5. Paper V  
The association between miR-205 expression and HPV status was analyzed with the 
Mann-Whitney U-test with continuity correlation. The association between miR-205 
expression and diagnosis (including cytology and histology) was analyzed by one-way 
ANOVA Kruskal-Wallis test. The correlation between miR-205 expression and age 
was analyzed using the Spearman rank-order correlation test. All statistical tests were 
two-sided and the null hypothesis of difference was rejected at a significance level of 
p<0.05. 
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4 6. RESULTS 
 
6.1. PAPER I 
A comparison of liquid-based cytology and Pap smear as a screening method for 
cervical cancer. 
 
Results from screening 137 Pap smears showed: ASCUS in 11 (8%) samples, LSIL in 
40 (29%), HSIL, ASC-H, and SCC in 56 (41%), while two samples showed atypical 
glandular lesions (AGUS). Twenty-eight (20%) samples were considered to be WNL. 
Samples prepared using LBC technique showed fewer cases of ASCUS, (6 cases, 4%), 
while LSIL was found in 44 (32%) samples, and HSIL and more advanced lesions in 
60 (44%). AGUS was found in 2 samples, while 25 (18%) LBC samples were 
considered to be WNL. CIN2+ cases were more common, while ASCUS was less 
common compared with Pap smear results (Figure I, Paper 1) 
 
The 28 (20%) women with normal Pap smears underwent simultaneous biopsy, with 
results showing CIN2+ lesions in 12 (43%) cases. Correspondingly, of the 25 benign 
LBC samples, 9 (36%) had CIN2+ lesions on biopsy. Of the 109 Pap smears with 
abnormal findings of any grade, 65 (60%) cases showed CIN2+ lesions, while of 112 
LBC samples, 68 (61%) had CIN2+ lesions (Table I and II, Paper 1). The sensitivity 
for detecting CIN2+ lesions was 47% for Pap smear and 66% for LBC. Concordance 
with histological findings was 37% for Pap smear, while the corresponding figure for 
LBC was 53%; the difference was statistically significant (p=0.011). 
 
 
6.2. PAPER II. 
Liquid-based Cytology with HPV Triage of Low-grade Cytological Abnormalities 
Versus Conventional Cytology in Cervical Cancer Screening. 
 
In this study, histological diagnoses were available for about 80% of all women, with 
reported cytological abnormalities. Similar detection rates for pathological findings 
between LBC+HPV triage and conventional cytology (Pap smear) in cases where 
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CIN2+ and CIN3+ were confirmed during introduction of the LBC technique. When 
LSIL was diagnosed among HR-HPV negative women the rate of abnormal cytological 
findings was significantly higher using LBC+HPV triage compared with conventional 
cytology (Pap smear). However, when LSIL was not diagnosed among HR-HPV 
negative women (whose findings were diagnosed as WNL), total abnormal findings 
were lower using LBC+HPV triage compared with conventional cytology (Pap smear).  
The study reflects the learning process that occurs when implementing new laboratory 
technology. Our study may have an impact on performance thus staff at all levels 
(midwives, cytotechnologists and cytopathologists) had extensive experience with the 
conventional screening, but limited experience with the slightly different criteria of 
LBC. The performance of LBC improved over time and similar with the Pap smear. 
The improved attention in the cytology interpretation may have had an impact of both 
screening performances. 
 
 
6.3. PAPER III 
p16INK4a immunocytochemistry in liquid-based cervical cytology: Is it feasible 
for clinical use? 
 
Of 118 LBC samples, 111 (94%) had sufficient material for immunocytochemistry, 
from which five were excluded due to insufficient histological follow-up, leaving a total 
of 106 samples for immunocytochemistry. Of these 106 LBC samples, 13 (12%) were 
classified as WNL, 40 (37%) showed LSIL and 49 (46%) showed HSIL. Two LBC 
samples had ASCUS and one was classified as AIS. 
Of 106 LBC samples, 10 (9%) showed strong p16 INK4a reactivity, 28 (26%) moderate 
and 19 (18%) showed weak p16 INK4a.reactivity, while 68 (64%) of the total of 106 cases 
showed weak or no reactivity (Tabel II, Paper 3). 
 
The intensity of p16 INK4a reactivity correlated with the cytology classification. In one 
normal case and in all cases with low-grade lesions, there was weak reactivity to p16 
INK4a
. Thirty-four of 49 (69%) HSIL samples showed moderate or strong reactivity. 
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Sensitivity for detecting HSIL with p16 INK4a staining was 0.60 (CI: 95%; 0.50-0.70) 
and specificity was 1.0 (CI: 95%; 0.77-1.0); PPV was 1.0 (CI: 95%; 0.92-1.0) 
 
Histological follow-up of the 106 cervical lesions showed benign findings in 19 (18%) 
cases, CIN1 in 26 (25%), CIN 2 in 28 (26), CIN3 in 30 (28%) SCC in 1 case, while two 
were classified as AIS. The degree of p16 INK4a.reactivity was also correlated to 
histological CIN classification (Table I, Paper 3). Sensitivity for detecting CIN2+ with 
p16 INK4a.immuncytochemical staining was 0.59 (CI: 95%; 0.49-0.69), specificity was 
0.94 (CI: 95%; 0.68-1.0), and PPV was 0.98 (CI: 95%; 0.89-1.0). 
 
 
6.4. PAPER IV 
High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia 
in high-risk HPV-positive women with minor cytological abnormalities. 
 
Of 112 LBC samples from women with minor cytological abnormalities, 108 (96%) 
had sufficient residual cell suspension for immunocytochemistry. Four samples were 
excluded due to insufficient material. 
Histology: 23 (22%) cases were classified as WNL, 43 (41%) as CIN1, 23 (22%) as 
CIN2, and 15 as CIN3+ (Table III, Paper 4). 
The most common HPV type was HPV16, found in 33% of samples, followed by 
HPV51 (20%), HPV31 (16%), HPV52 (11%) and HPV56 (11%). Multiple infections 
were found in 28 women. 
Among HR-HPV-positive women, 48 (46%) were positive for L1 protein, while the 
remaining 56 samples (54%) were L1-negative. Expression of L1 protein varied among 
different HPV types. The HPV types that expressed L1 most frequently were HPV56 
(80.0%), HPV45 (60.0%), HPV52 (58.3%) and HPV51 (52.4%) (Table II, In the Paper 
4). 
L1 expression by histological result: Reactivity to HPV L1 capsid protein was found in 
13 of 23 (56%) WNL samples, 26 of 43 (60%) CIN1 samples and 11 of 38 (29%) 
CIN2+samples. Thus expression of L1 correlates negatively with CIN grade (p=0.012) 
by Pearsson's Chi-square test (Table II). In a univariate logistic regression model using 
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CIN2+ as an outcome, absence of HR-HPV L1 expression at enrolment was a predictor, 
with an OR of 3.2 (95% CI, 1.081-9.417) for progression to CIN2+. 
 
Progression to CIN2+ among L1-positive women infected with HR-HPV, including 
HPV16, was found to be 35.3%, compared to only 15.4% in the group infected with 
both HR- and LR-HPV types (Table IV in Paper 4) stepwise logistic regression analysis 
shows (OR 4.46, CI, 1.4-14.212; P=0.0115). Among 13 HPV16-positive CIN1 cases, 
L1 expression was found in 8 (61.5%), whereas L1 expression was only in found in 
only 2 of 15 (13%) HPV16-positive CIN2+ cases (P=0.026). 
 
We found that among women with CIN2+, HPV16 L1 expression was rare (13.3%). 
We show that 25.0% of women infected with HR-HPV only progressed to CIN2+. In 
the group of CIN2+ cases infected with both HR- and LR-HPV types, we found a much 
higher proportion of women that progressed to CIN2+ (35.7%) (Table V, Paper 4).  
In our limited material we showed that different HR-HPV types in combination with 
loss of L1 expression have different oncogenic potential for the development of CIN2+. 
 
 
 
Tabel.II. HPV L1 reactivity correlated to histological diagnosis. 
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6.5. PAPER V 
Expression of microRNA in liquid based cytology, a possible prognostic marker 
for cervical cancer? 
 
A total of 127 LBC samples were collected from women who participated in the 
cervical screening program between 2008 and 2012 in Stockholm. Among these 
samples, histology was available for 109 of 127 (86%) samples. 
Cytology: Of 127 women, 19 (15%) cases were classified as WNL, 24 (19%) as LSIL, 
77 (61%) as HSIL and 7 (6%) women had squamous cell carcinoma. 
Histology: Histology showed 10 (9%) lesions classified as WNL, 21 (19%) as CIN1, 
26 (24%) as CIN2, 42 (39%) as CIN3 and 10 (9%) women had squamous cell 
carcinoma. 
The detailed information for each patient is listed in (Table S1, Paper 5). The summary 
of the clinical features is shown in (Table 1, Paper 5).  
Frequency of HR-HPV DNA detection: One hundred samples out of 127 (78.7%) have 
available HPV screening information. In the study population 74 women were HPV-
positive, of whom 68 (92%) had various HR-HPV types, while 42 (57%) had detectable 
HPV16 or HPV18. (Table S1, Paper 5). 
 
Using relative quantification method (2-∆CT), as normalized to RNU6B, we calculate the 
relative expression of miR-205 in the 127 liquid-based cytology samples. We performed 
Spearman Rank Order correlation analysis to investigate the associations of miR-205 
expression and ages. The study showed no significant correlation with age (R=-0.099, 
P=0.27) indicating miR-205 expression were not associated with ages. By performing 
Mann-Whitney U-test, we analyzed the associations between miR-205 expression and 
HPV presence in 100 available samples. There was no statistically significant difference 
between HPV-positive and HPV-negative samples (P=0.51), indicating miR-205 
expression was not associated with HPV infection in cervical cancers. By performing 
one-way ANOVA Kruskal-Wallis test, we compared the expression of miR-205 within 
different progression groups based on cytology diagnosis, histology diagnosis and final 
diagnosis (P=0.98, 0.97 and 0.75, respectively). Unfortunately, we could not observe 
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significant difference between groups, indicating that miR-205 expression alone could 
not distinguish the progression of cervical cancer in liquid-based cytology samples.  
 
The study also evaluated the correlation between miR-205 expression and various 
disease-related features (age, HPV, cytology, histology) by using the two-tailed chi-
square test; no statistical differences were observed. 
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5 7. DISCUSSION 
 
Organized cervical cancer screening based on Pap smears has considerably reduced the 
incidence of cancer, but sensitivity for detecting CIN is limited when using a single test. 
(Nanda et al., 2000). LBC technology has now become an established method for 
improving screening performance. 
 
In study I sensitivity for detecting CIN2+ was greater in LBC samples (66%) than in 
conventional Pap smear (47%). Even though the LBC specimens were prepared from 
residual Pap smear material, LBC was more sensitive for the detection of HSIL, while 
reducing the rate of ASCUS findings. This improved diagnostic performance may relate 
to better preservation of cell morphology, as demonstrated in other studies (Hoelund, 
2003; Schledermann, et al., 2006; Strander, et al., 2007). LBC methodology entails 
immediate fixation, which eliminates problems from drying artifacts, while filtration 
reduces obscuring blood and inflammatory cells, thereby improving performance. 
Correlation between histological diagnosis and LBC was 53%, but significantly lower 
for Pap smear, only 37%. 
 
Encouraged by these results, we carried out prospective performance testing using a test 
design similar to that used by others (Strander, et al., 2007). Thus samples from the 
population-based cervical screening program were randomly obtained either through 
conventional Pap smears or through LBC samples, culminating in two groups, each 
with over 4000 samples. When ASCUS or LSIL were identified in the LBC group, 
supplementary HPV DNA genotyping was obtained. Unlike previous studies 
(Kotaniemi-Talonen, et al., 2005; Strander, et al., 2007), our study showed no 
significant difference in screening performance between the two groups (, with similar 
detection rates and PPVs for high-grade lesions. 
 
This study, however, was conducted shortly after the introduction of LBC technique; 
consequently the results are likely to reflect the learning curve. Initially, when the study 
began and despite years of experience of conventional screening, our cytotechnologists 
and cytopathologists had limited experience with this new technique. 
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At first, subtle LBC findings were difficult to recognize. Nevertheless, this new 
technique was introduced with no negative impact on laboratory performance. 
Interestingly, improved performance was seen with both LBC and Pap samples over 
time. One reason may be the interest generated in the new technology, resulting in 
discussion among staff regarding the enhanced nuclear and cytoplasmic morphology. 
LBC preparations, with more even distribution and fewer overlapping cells are easier 
to interpret. We also found that continuous monitoring of diagnostic performance is 
important in order to balance the risk of over-diagnosis with over-confidence at the 
other end of the spectrum. Over-diagnosis, associated with reactive or degenerative 
conditions, is a minor issue given the availability of supplementary HPV DNA testing. 
Effective use of complementary HPV analysis can improve specificity for identifying 
women at risk of developing cxca. 
 
Modern technology allows us to tolerate a higher level of low-grade cytological 
screening abnormalities because LBC and HPV triage improve sensitivity for detection 
of CIN2+ (Arbyn, et al., 2004). The negative predictive value of HR-HPV analysis is 
very high; the virtual exclusion of any risk of precancerous lesions in HPV-negative 
cases is unlikely to decrease sensitivity for CIN2+ detection (Froberg, Johansson, 
Hjerpe, & Andersson, 2008). Although implementation of LBC did not initially 
improve screening performance, it allows for ancillary analyses that make it 
unnecessary to call women back for additional sampling, thereby avoiding added costs 
as well as many of the errors associated with repeat sampling. 
 
The subsequent studies aimed to evaluate potential diagnostic and prognostic markers. 
The “reflex test” concept makes it possible to demonstrate the presence and elevated 
expression of the p16 INK4a protein. Accumulation of p16 INK4a in the cell nucleus results 
from impaired retinoblastoma protein (pRb) function. The E7 protein from HR-HPV 
disrupts pRb function, resulting in free E2F that stimulates expression of p16 INK4a. 
Therefore the resulting accumulation of p16 INK4a protein has been proposed as a 
biomarker to identify dysplastic cells that may indicate a premalignant condition. Thus 
overexpression of p16 INK4a protein in dysplastic cells indicates active expression of HR-
 60 
HPV oncogene E7. This protein could therefore serve as a surrogate marker for 
oncogene expression in precancerous lesions. 
 
Accumulation of p16 INK4a can be demonstrated by immunocytochemistry and may 
improve the potential to distinguish between premalignant and reactive cells (Bibbo, et 
al., 2002; Klaes et al., 2001). We wanted to evaluate the potential to make this 
distinction using immunocytochemistry with Papanicolaou as counterstain. While most 
dysplastic cells showed strong p16 INK4a antibody reactivity, reactivity in metaplastic 
and glandular cells was weak (Negri et al., 2006). Such weak reactivity is more likely 
to be associated with reactive cellular stress than with a premalignant process. 
 
The study also showed that the intensity of p16 INK4a reactivity correlated with CIN 
classification as assessed by both histology and cytology. Strong reactivity was 
associated with high-grade lesions, while only one of thirteen cases assessed to be WNL 
showed any reactivity, and only on a weak level, thereby indicating a high PPV for this 
technique. Conversely, absence of p16 INK4a reactivity was seen in only 5 of 49 HSIL 
cases, indicating high sensitivity for detection of precancerous lesions. Absence of 
reactivity may indicate absence of cells expressing E7 in the sample. 
 
Two different p16 INK4a kits from the same manufacturer were assessed. After testing 
the first immunocytochemical staining kit, we tested the second one, purported to be 
more sensitive. We tested 37 samples with mild to moderate cytological abnormalities. 
Although the second kit showed slightly stronger immunoreactivity in some cases, 
despite the improved reagents the detection rates remained unchanged. 
 
Demonstration of p16 INK4a protein may prove useful as an ancillary screening test to 
indicate HPV DNA activity in premalignant changes. Sensitivity, however, may be too 
low to replace HPV DNA testing. A possible alternative role for this test may be to 
identify HR-HPV infections that are not yet oncogenically active. Such an application 
has been suggested for ASCUS- or LSIL-positive samples in combination with positive 
HPV triage, to help avoid unnecessary follow-up of negative cases (Carozzi et al., 2008; 
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Carozzi et al., 2013; Cuschieri & Wentzensen, 2008; Wentzensen & von Knebel 
Doeberitz, 2007). 
 
A more recent development is to combine p16 INK4a and Ki-67 in a dual-staining process. 
Currently, this immunocytochemical combination has been more thoroughly 
investigated than the initial studies based on p16 INK4a single-staining (Bergeron et al., 
2010; Denton et al., 2010; Trunk et al., 2004). Single-staining requires morphologic 
interpretation of immunoreactive cells to distinguish cells showing dysplasia from other 
reactive processes such as samples showing squamous metaplasia and endocervical 
cells (Roelens, et al., 2012). The p16 INK4a /Ki-67 dual-staining technique has also been 
suggested as a novel approach to screen for precancerous lesions in young HR-HPV 
positive women (Denton, et al., 2010; Ikenberg et al., 2013; Petry, et al., 2011; 
Wentzensen et al., 2014). 
 
In addition, the HPV L1 capsid protein has previously been shown to be a potential 
prognostic marker. This protein is produced in the superficial squamous cell layer 
during productive HPV infection (H. zur Hausen, 2002). Expression of this protein may 
signal possible spontaneous regression of the dysplastic lesion (Mehlhorn, et al., 2014). 
The L1 protein may initiate clearance of the infection and prevent it from becoming 
persistent. Absence of this protein expression may indicate successful avoidance of the 
innate immune response by infected cells, thereby enabling persistent infection which 
contributes to carcinogenesis. Earlier studies have shown (Grapsa et al., 2014; Griesser, 
et al., 2004; Hilfrich & Hariri, 2008) that immunocytochemical assessment of HPV L1 
protein status may be important to predict outcome of minor cytological abnormalities 
and may perhaps serve as a better indicator of risk then presence of HR-HPV DNA. 
 
For ethical reasons, it is not possible to monitor the importance of L1 expression over 
time by registering outcomes of infection. When evaluating the importance of HPV L1 
expression in minor cytological abnormalities, we found that protein expression 
correlates negatively with CIN grade, which is even more apparent during infection 
with the most oncogenic HPV types. L1 expression was commonly found in normal 
and LSIL samples, but rarely in histologically confirmed high-grade lesions. Of 13 L1-
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positive women infected with HPV16, only two (15%) progressed to CIN2+, while the 
corresponding rate among L1-negative women with HR-HPV was 35%. Among 
samples containing HPV16, (Paper IV), L1 reactivity was found in 62% of cases where 
the reading was CIN1, while the corresponding frequency was significantly less. 13%. 
A trend was also found indicating higher expression of L1 protein in cases of 
simultaneous infection with HR-HPV and LR-HPV. 
 
The risk of developing CIN2+ was similar among L1-positive women co-infected with 
both HR-HPV and LR-HPV types and among those infected with HPV16 alone. 
Another study showed similar findings (Luostarinen et al., 1999). The low proportion 
of CIN2+ (15%) among L1-positive cases infected with HPV16 is noteworthy 
considering that HPV16 is one of the most oncogenic types. While 71% of L1-negative 
cases progressed to CIN2+, only 29% of all L1-positive cases did so. Interestingly, since 
L1 expression indicates productive infection, it may be postulated that the cells harbor 
the HPV virus episomally, without integration into the human genome. Once virions 
are released they may be exposed to the immune system, hypothetically producing an 
immune response and clearance of infection. In such a scenario, L1 capsid protein 
expression would have prognostic value. 
 
Simultaneous immunocytochemical demonstration of p16INK4a and HPV L1 capsid 
protein as complementary markers can be used to grade precancerous lesions. 
(Alshenawy, 2014; Balan et al., 2010; Byun et al., 2013; Gatta et al., 2011; Izadi-Mood, 
Sarmadi, Eftekhar, Jahanteegh, & Sanii, 2014; Yoshida et al., 2008). While L1 
reactivity stems mainly from superficial cells where LSIL is present, p16INK4a reactivity 
derives from cells within the entire epithelium, indicating deeper HSIL or SCC lesions. 
 
Dysregulated miRNA profiles have been observed to play a functional role in different 
human cancers including cervical cancer and may be used as a diagnostic tool. Since 
most such studies were based on tissue samples, little is known about whether altered 
expression of these miRNAs can be adequately seen in LBC samples. In this study, we 
choose miR-205 as an example to evaluate the possibility of miRNA detection by RT-
qPCR method in liquid-based cytology. miR-205 is considered to be of particular 
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interest in cxca, where it is often significantly overexpressed compared with normal 
cells. (Lui, et al., 2007; Witten, et al., 2010; Xie, et al., 2012). miR-205 has been shown 
to suppress cell migration/invasion, through the process of epithelial-to-mesenchymal 
transition, and may serve as an oncogene or tumor suppressor gene, depending on cell 
type. 
 
Unfortunately, no significant correlation could be found between expression of miR-
205 HPV status and morphology of lesion when analyzing LBC. A slight but not 
significant trend toward increased expression was found with increasing CIN grade. 
Here we show that RT-qPCR detection is not ideal for quantification of miRNAs in 
liquid-based cytology samples using RNAs extracted from the mixed cell population, 
which contain a large amount of normal cells. As evaluated the cell population under 
microscopy in the 10 cancer cases, we observed the involved cells of diagnostic interest 
that are expected to express increased levels of miRNA constitute only a minute 
proportion of total cell numbers and those cells are often also necrotic and we know that 
necrosis will affect the quality of RNA molecules.  
 
Theoretically, other single cell based detection method such as in situ hybridization (Ge, 
Zhang, Liu, Yu, & Chu, 2014; Nielsen, 2012) or microfluidic flow cytometry (Wu, 
Piccini, Koh, Lam, & Singh, 2013; Wu, Piccini, & Singh, 2014) is a practical method 
for liquid-based cytology. There is still a long way to put them successfully applicable 
in clinical usage. To better address this question, more samples specially paired or series 
samples from same patient are needed.  
  
 64 
6 8. CONCLUSIONS  
 
The first study shows that LBC better preserves morphology, improves sensitivity for 
detection of CIN2+ and correlates better with histopathology than conventional Pap 
smears. LBC testing also allows for ancillary analyses using residual cell suspension.  
 
Performance declined somewhat when this technique was implemented in the 
population-based screening program. Nevertheless, the new technique achieved 
screening performance equivalent to conventional cytology. The second study includes 
the material from this period, which reflects the learning curve from the introduction of 
the new technology. 
 
Immunoreactivity to p16 INK4a correlates with the presence of dysplastic lesions and was 
largely absent in normal cells. Staining indicates oncogenic HPV activity and may 
therefore find a role in ancillary screening.  
 
Similar reactivity to the HPV L1 capsid protein was associated with mild cellular atypia 
and was essentially absent in cases of histologically confirmed high-grade lesions. 
These findings may support the hypothesis that L1 expression is associated with 
clearing of the infection. Together these two markers may improve identification of 
precancerous lesions. 
 
The fifth study shows that the LBC technique is inadequate to demonstrate how altered 
expression levels of tumor-specific miR-205 reflect the status of established cxca. The 
low number of tumor cells in LBC samples, as well as the presence of tumor necrosis, 
make microRNA analysis unsuitable as an indicator for progression to an invasive 
condition. 
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7 9. FUTURE PERSPECTIVES 
 
Today we know that HR-HPV testing has high sensitivity for the detection of advanced 
precancerous lesions (Arbyn, et al., 2012; Bulkmans et al., 2007; Ronco et al., 2010). 
However, the specificity for use as a screening test is limited since most HPV infections 
are transient and only a small proportion of the screening population has persistent 
infection associated with risk for progression to malignancy (Koliopoulos et al., 2007; 
Ronco et al., 2006). Due to the high prevalence of HPV among young women, HPV 
testing is not recommended as a primary screening tool in younger age groups (Saslow 
et al., 2012Saslow et al., 2012). Immunocytochemical demonstration of p16INK4a / Ki-
67 dual-staining combined with testing for HPV L1 capsid protein reactivity may be 
helpful when reflex cytology is inconclusive. Along with cell morphology, these three 
tests may improve identification of women at risk of oncogenic progression. Such use 
in clinical practice remains to be evaluated. 
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